SLC5A2 and plasma cell myeloma: Additionally, a suggestive association between SGLT2 inhibition and the following malignancies was also confirmed: oral cavity and pharyngeal cancer (beta: -0.010 [-0.017, -0.002], P = 0.011), small intestinal cancer (beta: 0.004 [0.000, 0.008], P = 0.037), rectal cancer (beta: -0.011 [-0.019, -0.004], P = 0.005), ovarian cancer (beta: -1.230 [-2.154, -0.305], P = 0.009), and multiple myeloma (beta: -0.008 [-0.014, -0.001], P = 0.017).